Ertugliflozin
Brand: Steglatro (US/EU)
Antidiabetic
SGLT2 inhibitor
Pharmacokinetics
| Half-life | 17 hours |
| Tmax | 1 h |
| Bioavailability | 70 % (approx) |
| Protein Binding | 93 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Typical dose 5–15 mg od; follow renal thresholds per indication. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Genital infections, polyuria, dehydration, euglycemic DKA (rare)
Contraindications:
Dialysis
Precautions:
Educate on sick-day rules; monitor volume status; hold perioperatively